A multi-center, open-label, randomized study to explore efficacy and safety of baricitinib in active primary Sjogren’s syndrome patients

BACKGROUND: Primary Sjogren’s syndrome (pSS) is a systemic autoimmune disease involving multiple organ systems. The Janus kinase/signal transduction and activator of transcription (JAK/STAT) signaling pathway is a key pathway involving the pathogenesis of pSS. Baricitinib, a selective JAK1 and JAK2...

Descripción completa

Detalles Bibliográficos
Autores principales: Bai, Wei, Yang, Fan, Xu, Huji, Wei, Wei, Li, Hongbin, Zhang, Liyun, Zhao, Yi, Shi, Xiaofei, Zhang, Yan, Zeng, Xiaofeng, Leng, Xiaomei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9930286/
https://www.ncbi.nlm.nih.gov/pubmed/36793118
http://dx.doi.org/10.1186/s13063-023-07087-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9930286/
https://www.ncbi.nlm.nih.gov/pubmed/36793118
http://dx.doi.org/10.1186/s13063-023-07087-5

Ejemplares similares